Alpha-1 Antitrypsin Levels and Phenotypes in Patients with Asthma and COPD in Appalachian East Tennessee.

IF 4.1 3区 医学 Q2 RESPIRATORY SYSTEM
Rajiv Dhand, Ghassan Wadi, Jennifer Ferris, Gulsah Sofia Onar, Paul Terry, Robert Eric Heidel, Yuliya Nemykina
{"title":"Alpha-1 Antitrypsin Levels and Phenotypes in Patients with Asthma and COPD in Appalachian East Tennessee.","authors":"Rajiv Dhand, Ghassan Wadi, Jennifer Ferris, Gulsah Sofia Onar, Paul Terry, Robert Eric Heidel, Yuliya Nemykina","doi":"10.2147/COPD.S619871","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Alpha-1 Antitrypsin Deficiency (A1ATD) is associated with an increased risk of emphysema and chronic obstructive pulmonary disease (COPD). In view of the high prevalence of chronic respiratory diseases in East Tennessee and limited data on A1AT phenotypes in this area, we determined A1AT allele frequency among patients with COPD, asthma, or asthma-COPD overlap (ACO) in our clinic population.</p><p><strong>Patients and methods: </strong>We conducted an IRB-approved retrospective analysis of patient demographics, medical history, comprehensive pulmonary function tests (PFTs), and serum A1AT levels and phenotypes in a cohort of general pulmonary clinic patients with COPD, asthma, or ACO at the University of Tennessee Medical Center in Knoxville, TN. We employed descriptive and nonparametric statistical methods for data analysis, and an alpha value < 0.05 was considered statistically significant.</p><p><strong>Results: </strong>In this cohort of 177 patients (mean age 63.2 ± 11.9 years), most were white (94.4%), female (59.3%), former or current smokers (79.1%), and homozygous for the normal PiMM A1AT phenotype (78.5%). Heterozygous A1AT phenotypes PiMS, PiMZ, PiSZ, and PiXZ were found in 23.9%, 20%, and 8.3% of patients with COPD, ACO, and asthma, respectively. Compared with PiMM, serum A1AT levels were significantly lower with PiMZ, PiSZ, and PiXZ phenotypes (p < 0.001). PFTs did not differ among A1AT phenotypes. In fact, there was a weak negative correlation between serum A1AT levels and forced vital capacity (r = -0.29; p = 0.01) and diffusion capacity for carbon monoxide (r = -0.27; p = 0.03).</p><p><strong>Conclusion: </strong>Among our East Tennessee cohort with COPD, asthma, or ACO, we found a 2- to 6-fold higher prevalence of heterozygous A1AT phenotypes than a national survey of US veterans. Further investigation through larger, prospective, population-based studies is needed to determine the clinical relevance of the higher prevalence of A1AT heterozygotes in this region.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"21 ","pages":"619871"},"PeriodicalIF":4.1000,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573784/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S619871","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Alpha-1 Antitrypsin Deficiency (A1ATD) is associated with an increased risk of emphysema and chronic obstructive pulmonary disease (COPD). In view of the high prevalence of chronic respiratory diseases in East Tennessee and limited data on A1AT phenotypes in this area, we determined A1AT allele frequency among patients with COPD, asthma, or asthma-COPD overlap (ACO) in our clinic population.

Patients and methods: We conducted an IRB-approved retrospective analysis of patient demographics, medical history, comprehensive pulmonary function tests (PFTs), and serum A1AT levels and phenotypes in a cohort of general pulmonary clinic patients with COPD, asthma, or ACO at the University of Tennessee Medical Center in Knoxville, TN. We employed descriptive and nonparametric statistical methods for data analysis, and an alpha value < 0.05 was considered statistically significant.

Results: In this cohort of 177 patients (mean age 63.2 ± 11.9 years), most were white (94.4%), female (59.3%), former or current smokers (79.1%), and homozygous for the normal PiMM A1AT phenotype (78.5%). Heterozygous A1AT phenotypes PiMS, PiMZ, PiSZ, and PiXZ were found in 23.9%, 20%, and 8.3% of patients with COPD, ACO, and asthma, respectively. Compared with PiMM, serum A1AT levels were significantly lower with PiMZ, PiSZ, and PiXZ phenotypes (p < 0.001). PFTs did not differ among A1AT phenotypes. In fact, there was a weak negative correlation between serum A1AT levels and forced vital capacity (r = -0.29; p = 0.01) and diffusion capacity for carbon monoxide (r = -0.27; p = 0.03).

Conclusion: Among our East Tennessee cohort with COPD, asthma, or ACO, we found a 2- to 6-fold higher prevalence of heterozygous A1AT phenotypes than a national survey of US veterans. Further investigation through larger, prospective, population-based studies is needed to determine the clinical relevance of the higher prevalence of A1AT heterozygotes in this region.

东田纳西州阿巴拉契亚地区哮喘和慢性阻塞性肺病患者α -1抗胰蛋白酶水平和表型
目的:α -1抗胰蛋白酶缺乏症(A1ATD)与肺气肿和慢性阻塞性肺疾病(COPD)风险增加有关。鉴于东田纳西州慢性呼吸系统疾病的高患病率和该地区A1AT表型数据有限,我们在临床人群中确定了COPD、哮喘或哮喘-COPD重叠(ACO)患者的A1AT等位基因频率。患者和方法:我们在田纳西州诺克斯维尔的田纳西大学医学中心进行了一项irb批准的回顾性分析,对患者人口统计学、病史、综合肺功能测试(PFTs)、血清A1AT水平和表型进行了回顾性分析,研究对象是一组患有COPD、哮喘或ACO的普通肺部临床患者。我们采用描述性和非参数统计方法进行数据分析,alpha值< 0.05被认为具有统计学意义。结果:在177例患者(平均年龄63.2±11.9岁)中,大多数是白人(94.4%),女性(59.3%),曾经或现在吸烟(79.1%),纯合子为正常的PiMM A1AT表型(78.5%)。杂合子A1AT表型pim、PiMZ、PiSZ和PiXZ分别存在于23.9%、20%和8.3%的COPD、ACO和哮喘患者中。与PiMM相比,PiMZ、PiSZ和PiXZ表型的血清A1AT水平显著降低(p < 0.001)。pft在A1AT表型之间没有差异。事实上,血清A1AT水平与强迫肺活量(r = -0.29, p = 0.01)和一氧化碳扩散能力(r = -0.27, p = 0.03)呈弱负相关。结论:在我们的东田纳西州COPD、哮喘或ACO队列中,我们发现杂合A1AT表型的患病率比全国调查的美国退伍军人高2- 6倍。需要通过更大规模、前瞻性、基于人群的研究进行进一步调查,以确定该地区A1AT杂合子较高患病率的临床相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
10.70%
发文量
372
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书